Texas-based Mystic Pharmaceuticals has announced that its new Arrowfish intranasal delivery system is now available. The platform, which incorporates Mystic’s VersiDoser and VRx2 blister systems, can deliver either liquid or dry powder formulations, in either mono- or multi-dose versions, and can be customized for use with a particular drug or biologic.
Mystic CEO Timothy Sullivan commented, “The development phase of the ArrowFish delivery system was accelerated from years to months demonstrating the power of our engineered platform approach.”
Read the Mystic Pharmaceuticals press release.
